IP Library Granted Patent US 8,680,132
Granted Patent B2
US 8,680,132 · App. 13/294,315 · Granted Mar 25, 2014

Spiro-oxindole MDM2 antagonists

Inventors: Shaomeng Wang (Saline, MI); Wei Sun (Yunnan, CN)
Assignees: The Regents of the University of Michigan; Ascenta Licensing Corporation; Sanofi
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,680,132
App. No.
13/294,315
Granted
Mar 25, 2014
Kind
B2
Abstract

Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.

Claims (8)

1. A compound having the structure:

wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is a substantially pure stereoisomer, or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method of treating a patient comprising administering to the patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the patient has sarcoma, melanoma, lung cancer, colon cancer, prostate cancer, breast cancer, choriocarcinoma, retinoblastoma, stomach carcinoma, lymphoma, multiple myeloma, or leukemia.

5. The method of claim 4 , wherein the patient has liposarcoma or melanoma.

6. The method of claim 4 , further comprising administering to the patient one or more anticancer agents.

7. A kit comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt thereof, to a patient having cancer.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2013
From: ASCENTA THERAPEUTICS, INC.
To: ASCENTA LICENSING CORPORATION
Reel/Frame 030319/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2013
From: GUO, MING
To: ASCENTA LICENSING CORPORATION
Reel/Frame 030319/0342 →
CONFIRMATORY LICENSE Recorded Dec 9, 2011
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027358/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: LEOPOLD, LANCE
To: ASCENTA THERAPEUTICS, INC.
Reel/Frame 027216/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: AMANING, KWAME; BARRIERE, CEDRIC; DEBUSSCHE, LAURENT; CARRY, JEAN-CHRISTOPHE
To: SANOFI
Reel/Frame 027216/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: WANG, SHAOMENG; SUN, WEI; ZHAO, YUJUN; KUMAR, SANJEEV
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 027216/0222 →
Continuity (5)
Provisional Application 61413094 · Nov 12, 2010
Provisional Application 61451968 · Mar 11, 2011
Provisional Application 61451958 · Mar 11, 2011
Provisional Application 61470992 · Apr 1, 2011
Related Publication 20120122947A1 · May 17, 2012